Sparenborg, Steven

Bupropion and naltrexone in methamphetamine use disorder

Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine

Substance Abuse Treatment and OutcomesOpioid Use Disorder Treatment

Cited by 281

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology

Cannabis and Cannabinoid ResearchForensic Toxicology and Drug Analysis

Cited by 206

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., et al. (2017) · Drug and Alcohol Dependence

Substance Abuse Treatment and OutcomesCannabis and Cannabinoid Research

Cited by 157

Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder

Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., et al. (2016) · Journal of Addiction Medicine

Substance Abuse Treatment and OutcomesOpioid Use Disorder Treatment

Cited by 25